Publications by authors named "A A Bedros"
The Implementation and Outcomes of Personalized Antihypertensive Therapy Based on Pharmacogenetic Testing: A Retrospective Study Examining Blood Pressure Control and Medication Tolerability.
Cureus
November 2024
Background: Hypertension management typically relies on standardized treatment regimens, which may not account for individual genetic variations that affect drug metabolism and response.
Objective: The objective of this study was to evaluate the effectiveness of personalized antihypertensive therapy, guided by pharmacogenetic testing, in terms of blood pressure (BP) control and medication tolerability.
Materials And Methods: A retrospective cohort study was conducted at Jinnah Postgraduate Medical Centre, Karachi, from January 2023 to December 2023.
Article Synopsis
- Variceal bleeding is a serious issue for patients with cirrhosis, leading to higher risks of complications and death, particularly after an initial occurrence.
- A systematic review assessed the effectiveness of endoscopic treatments like band ligation and TIPS, which showed better immediate outcomes, compared to pharmacological options like beta-blockers, which help manage long-term risks.
- The study emphasizes tailored treatment plans combining both approaches to improve patient results and calls for further research on long-term benefits and cost-effectiveness.
Traumatic brain injury (TBI) is a leading cause of mortality and long-term disability worldwide, and accurate imaging is essential for effective diagnosis, management, and prognosis. This systematic review evaluates the diagnostic capabilities of magnetic resonance imaging (MRI) compared to computed tomography (CT) in assessing TBI across various severities. Through a comprehensive search strategy, studies were selected that directly compared MRI and CT in TBI diagnosis, incorporating advanced MRI techniques such as susceptibility-weighted imaging and fluid-attenuated inversion recovery.
View Article and Find Full Text PDFArticle Synopsis
- Crohn's disease (CD) significantly affects patients' quality of life, and this review assesses the effectiveness and safety of upadacitinib, a JAK inhibitor, in treating it.
- The analysis included seven studies with 1,481 patients, and results showed upadacitinib outperforms placebo in achieving clinical remission and reducing inflammation quickly, often within five to six days.
- While the treatment has a generally acceptable safety profile, with risks like infections and laboratory abnormalities, it presents as a promising option for managing moderate to severe CD, particularly for those who have not responded to other therapies.
Purpose: We investigated research barriers among Jordanian medical postgraduates to understand the current context of the local health research landscape and improve scholarly output.
Methods: Using a validated questionnaire, Jordanian interns, residents, specialists, and consultants were examined for their perceived attitudes and barriers towards research. Participants were conveniently sampled from public, university, military, and private institutions.